Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH139210D
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company's pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Synthetic Biologics' SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Synthetic Biologics is headquartered in Rockville, Maryland, the US.

Synthetic Biologics Inc (SYN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13

Venture Financing 15

SeeChange Health Raises USD 3 Million In Venture Financing 15

Partnerships 16

Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16

Intrexon Enters into Partnership with Synthetic Biologics 17

Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18

Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19

Licensing Agreements 20

Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20

Equity Offering 22

Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22

Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23

Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24

Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26

Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28

Synthetic Biologics Completes Public Offering Of Shares For USD 13.2 Million 30

Synthetic Biologics Completes Private Placement Of Common Stock For USD 11 Million 31

Acquisition 32

Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32

Synthetic Biologics Inc-Key Competitors 33

Synthetic Biologics Inc-Key Employees 34

Synthetic Biologics Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

Aug 08, 2018: Synthetic Biologics reports second quarter 2018 operational highlights and financial results 36

May 08, 2018: Synthetic Biologics Reports First Quarter 2018 Operational Highlights And Financial Results 37

Feb 22, 2018: Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results 39

Nov 01, 2017: Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results 40

Aug 03, 2017: Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results 41

May 04, 2017: Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results 43

Mar 02, 2017: Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results 45

Corporate Communications 47

May 22, 2018: Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American 47

Mar 07, 2018: Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan 48

Dec 05, 2017: Synthetic Biologics Announces Management Changes 49

Product News 50

01/18/2017: Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA 50

Clinical Trials 51

Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study 51

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Synthetic Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13

SeeChange Health Raises USD 3 Million In Venture Financing 15

Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16

Intrexon Enters into Partnership with Synthetic Biologics 17

Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18

Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19

Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20

Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22

Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23

Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24

Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26

Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28

Synthetic Biologics Completes Public Offering Of Shares For USD 13.2 Million 30

Synthetic Biologics Completes Private Placement Of Common Stock For USD 11 Million 31

Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32

Synthetic Biologics Inc, Key Competitors 33

Synthetic Biologics Inc, Key Employees 34

Synthetic Biologics Inc, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Synthetic Biologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17840
Site License
USD 500 INR 35680
Corporate User License
USD 750 INR 53520

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com